No Data
Fengyuan Pharmaceutical: Report for the third quarter of 2024
Anhui Fengyuan Pharmaceutical (000153.SZ) released its performance for the first three quarters, with a net income of 0.147 billion yuan, a year-on-year increase of 3.40%.
Anhui Fengyuan Pharmaceutical (000153.SZ) released the third quarter report of 2024. In the first three quarters, the company achieved revenue...
Anhui Fengyuan Pharmaceutical (000153.SZ): The net income in the first three quarters was 0.147 billion yuan, a year-on-year increase of 3.40%.
Gelonghui October 30th | Anhui Fengyuan Pharmaceutical (000153.SZ) released the third quarter report for 2024. In the first three quarters of 2024, the company achieved revenue of 3.261 billion yuan, a year-on-year increase of 1.16%; net income attributable to shareholders of the listed company was 0.147 billion yuan, a year-on-year increase of 3.40%; net income after deducting non-recurring gains and losses was 0.118 billion yuan, a year-on-year decrease of 9.64%; basic earnings per share 0.3169 yuan/share.
Anhui Fengyuan Pharmaceutical (000153.SZ): The company's product physiological saline is currently not exported to the usa.
Georg-Lonhui October 25th | Anhui Fengyuan Pharmaceutical (000153.SZ) stated on the investor interaction platform that the company's product physiological saline is currently not exported to the usa.
Fengyuan Pharmaceutical: 2024 Semi-Annual Report
Fengyuan Pharmaceutical: 2024 Semi-Annual Report Summary
No Data
No Data